A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years – Results from 1697 postmenopausal women in the N‑SAS BC05 trial: Arimidex extended adjuvant randomized study (AERAS) - Ohtani, S; Iijima, K; Higaki, K (San Antonio Breast Cancer Symposium, 2018)
Abstr. GS3-04